Canaccord last night initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $110 price target The firm says the company is executing “very well” in its transition to a commercial company with “strong launches” of Tryngolza and Dawnzera. Ionis has a “transformational milestone” in mid-2026 with the expected approval of Tryngolza in severe hypertriglyceridemia, a “very large market,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals initiated with a Buy at Canaccord
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- Ionis Pharmaceuticals resumed with an Outperform at Raymond James
- Ionis Pharmaceuticals price target raised to $111 from $100 at BofA
- Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors